PepGen Inc. (PEPG) - Q3 2025 10-Q Summary
Business Context and Reporting Period
PepGen Inc. is a clinical-stage biotechnology company developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases. This report covers the quarterly period ended September 30, 2025. The company is classified as an emerging growth company and a smaller reporting company. As of November 5, 2025, there were 68,748,224 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(18.0) million | $(21.4) million | $(71.3) million | $(67.7) million |
| Operating Expenses | $18.7 million | $23.2 million | $73.9 million | $73.4 million |
| Cash & Cash Equivalents | $142.8 million (as of Sept 30, 2025) | |||
| Marketable Securities | ||||
| Total Liquidity | $163.7 million | |||
| Accumulated Deficit | $(342.8) million |
Material Changes vs. Prior Period
- Capital Raise: In September 2025, the company completed a public offering (the "2025 Offering"), selling 35.9 million shares at $3.20 per share, resulting in net proceeds of approximately $107.6 million. This significantly improved liquidity compared to the prior year.
- Program Discontinuation: In May 2025, PepGen voluntarily discontinued development of its Duchenne muscular dystrophy (DMD) candidate, PGN-EDO51, following clinical trial results that did not support further development. All DMD-related R&D activities are being wound down.
- Expense Reduction: Q3 2025 operating expenses decreased by $4.5 million compared to Q3 2024, driven by reduced personnel costs, lower manufacturing costs, and the cessation of the DMD program.
- Interest Income: Interest income decreased to $0.6 million in Q3 2025 from $1.8 million in Q3 2024, reflecting changes in cash deployment and market rates.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes current cash, cash equivalents, and marketable securities ($163.7 million) are sufficient to fund planned operations into the second half of 2027. The company previously disclosed substantial doubt about its ability to continue as a going concern, but this has been alleviated by the September 2025 capital raise.
- Clinical Progress: The company is focused on PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1).
- FREEDOM (Phase 1): Dose escalation concluded with the 15 mg/kg cohort. Topline data showed a mean splicing correction of 53.7% with a favorable safety profile.
- FREEDOM2 (Phase 2): Currently open in Canada and the U.K. Data from the 5 mg/kg cohort is expected in Q1 2026.
- Legal Proceedings: A putative shareholder class action lawsuit (Johnny Karam v. PepGen Inc.) was filed in June 2025 alleging misrepresentations regarding PGN-EDO51. The company intends to defend vigorously and has not recorded a loss estimate.
- Subsequent Event: On November 4, 2025, the Board approved an option repricing for 3.56 million eligible stock options to an exercise price of $4.53, subject to retention periods.
Investor Verification Checklist
- Verify the timeline and enrollment status of the FREEDOM2 Phase 2 trial for PGN-EDODM1.
- Monitor the status of the Karam shareholder litigation and potential settlement costs.
- Assess the burn rate relative to the $163.7 million cash runway and the timeline for the next potential capital raise.
- Review the impact of the option repricing on future stock-based compensation expenses.
- Confirm the wind-down costs associated with the discontinued PGN-EDO51 program.